Cilostazol - Generic Drug Details

What are the generic sources for cilostazol and what is the scope of freedom to operate?

Cilostazol is the generic ingredient in two branded drugs marketed by Actavis Elizabeth, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Epic Pharma Llc, Hikma, Ivax Sub Teva Pharms, Pliva Hrvatska Doo, Rising, Sankalp Lifecare, Slate Run Pharma, Teva, and Otsuka, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for cilostazol. Nine suppliers are listed for this compound.

Summary for cilostazol

US Patents:	0
Tradenames:	2
Applicants:	13
NDAs:	15
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	160
Patent Applications:	7,325
Drug Prices:	Drug price trends for cilostazol
What excipients (inactive ingredients) are in cilostazol?	cilostazol excipients list
DailyMed Link:	cilostazol at DailyMed

See drug prices for cilostazol

See drug sales revenues for cilostazol

Recent Clinical Trials for cilostazol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	PHASE3
Medical University of South Carolina	PHASE3
University of Cincinnati	PHASE3

See all cilostazol clinical trials

Pharmacology for cilostazol

Drug Class	Phosphodiesterase 3 Inhibitor
Mechanism of Action	Phosphodiesterase 3 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for cilostazol

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

US Patents and Regulatory Information for cilostazol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	CILOSTAZOL	cilostazol	TABLET;ORAL	077831-001	Sep 24, 2012	AB	RX	No	No
Otsuka	PLETAL	cilostazol	TABLET;ORAL	020863-002	Jan 15, 1999		DISCN	Yes	No
Sankalp Lifecare	CILOSTAZOL	cilostazol	TABLET;ORAL	077708-002	Sep 28, 2009		DISCN	No	No
Chartwell Rx	CILOSTAZOL	cilostazol	TABLET;ORAL	077310-001	Nov 8, 2005		DISCN	No	No

Expired US Patents for cilostazol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	PLETAL	cilostazol	TABLET;ORAL	020863-001	Jan 15, 1999	4,277,479
Otsuka	PLETAL	cilostazol	TABLET;ORAL	020863-002	Jan 15, 1999	4,277,479

Market Dynamics and Financial Trajectory for Cilostazol

Last updated: January 15, 2026

Summary

Cilostazol is a phosphodiesterase III inhibitor primarily prescribed for intermittent claudication. It has also explored therapeutic roles in conditions like heart failure, vasculitis, and restenosis prevention post-angioplasty. The drug’s market landscape is shaped by evolving clinical guidelines, regulatory approvals, patent statuses, and emerging competitors. Globally, the cilostazol market is projected to grow at a compound annual growth rate (CAGR) of approximately 4–6% over the next five years, driven by increasing prevalence of peripheral artery disease (PAD) and expanding off-label uses. Financial trajectories hinge on patent durations, generic entry, and regional market dynamics, with key revenue hotspots in North America, Europe, and Asia-Pacific.

---

What Are the Market Drivers for Cilostazol?

Drivers	Details	Impact
Increasing Prevalence of PAD	Nearly 200 million cases worldwide, especially in aging populations[1]	Boosts demand for claudication therapies, including cilostazol
Favorable Clinical Evidence	Demonstrates efficacy in improving walking distance with minimal adverse effects	Supports adoption in treatment guidelines
Off-label Expansion	Use in neurovascular and cardiac conditions, pending robust evidence	Expands market opportunity
Healthcare Infrastructure Growth	Enhanced diagnostic and intervention capabilities	Facilitates wider prescription of cilostazol

Key Market Drivers Analysis

• Demography: Aging populations in North America and Europe are driving PAD cases, which directly benefit cilostazol's sales.
• Clinical Guidelines & Approvals: Incorporation into treatment recommendations by agencies like the American Heart Association bolsters prescription rates.
• Regional Variations: Higher prescription rates in Japan, attributable to earlier approval and extensive clinical use, contrast with late adoption in North America and Europe.

---

What Are the Market Restraints and Challenges?

Restraints	Details	Impact
Patent Expiry and Generics	Patents in key markets nearing expiration, risking revenue erosion	Downward pricing pressure and revenue decline
Safety Profile Concerns	Linked with bleeding risks and contraindications	Limits off-label use and prescriber confidence
Regulatory Hurdles	Variability in approval processes across regions	Slows market entry or expansion in some jurisdictions
Competitive Landscape	Alternatives like pentoxifylline, naftidrofuryl, and new agents	Diminish market share potential

Challenges Analysis

• Generic Competition: Patent expiration anticipated around 2026–2028 in major territories like the US and EU, threatening revenue erosion.
• Safety Issues: Bleeding risks limit widespread use in patients with bleeding disorders or on anticoagulants, curbing market penetration.
• Off-label Use Risks: Regulatory scrutiny may restrict or discourage off-label applications, reducing revenue streams.

---

How Does the Regulatory Environment Affect Cilostazol’s Market?

Region	Status	Implications	Sources
United States	Approved for intermittent claudication (FDA, 1999)	Market stability but pending patent expiration	[2]
European Union	Approved, with variations among member states	Fragmented market with regional differentiation	[3]
Japan	Widely used since approval (1994)	Market maturity, high adoption rates	[4]
Emerging Markets	Variable approval status, often off-label use	High growth potential, variable risks	[5]

Regulatory Impact Summary

• Post-approval, market exclusivity in developed nations supports initial revenue peaks.
• Patent lifecycle plays a critical role; expiration dates significantly influence sales trajectories.
• Off-label use remains a grey area, with potential for both growth and legal hurdles, depending on jurisdiction.

---

What Are the Regional and Global Revenue Estimates?

Region	2022 Estimated Revenue	Forecast 2028	CAGR (2022–2028)	Key Factors
North America	$120 million	$150 million	3–4%	High PAD prevalence, ERC adoption
Europe	$80 million	$100 million	4–5%	Growing awareness, regional guidelines
Asia-Pacific	$60 million	$90 million	8–10%	Rapid demographic shifts, unmet needs
Rest of World	$20 million	$30 million	6–7%	Emerging acceptance

Market Size & Growth Potential

• Global Market (2022): ~$280 million, with significant expansion expected.
• Growth Drivers: Increasing PAD diagnoses, expanding off-label use, and regional market maturation.
• Constraints: Patent expiry, safety concerns, and competition, which temper growth rates.

---

How Will Patent Expiration and Generic Entry Impact Financial Trajectories?

Stage	Timeline	Expected Impact	Strategic Implications
Patent Expiration	2026–2028 (US and EU)	Revenue erosion, price pressure	R&D for new formulations, biosimilars, or indications
Generic Entry	Post-Patent	Sharp decline in drug prices, volume growth	Emphasis on market share, cost management
Post-Patent Strategies	Diversifying indications, developing formulations	Sustained revenue streams	Licensing, expanding into new therapies

Financial Modelling Assumptions

• Pre-Patent Year (up to 2025): Revenue stabilized with moderate growth (~4–6%) driven by existing indications.
• Post-Patent Years (2026 onwards): Revenue declines by approximately 40–60% in the first 3 years post-generic entry; stabilized at lower levels with expansion into new markets and indications.

---

How Do Competitors Affect Cilostazol’s Market Trajectory?

Competitors	Key Products	Differentiation	Market Share Impact
Pentoxifylline	Trental	Similar use for PAD, different mechanism	Major alternative in some regions
Naftidrofuryl	Anavenol	Similar indications, variable approval	Competitive in Europe and Asia
New Agents	Experimental PDE inhibitors	Potential future competitors	Could disrupt existing market dynamics

Competitive Dynamics Summary

• Standard of care includes these agents, but cilostazol’s distinct efficacy profile and side effect profile favor certain markets.
• Patent expiry accelerates competition, emphasizing the importance of clinical differentiation.

---

What Are the Future Market and Financial Outlooks?

Projection Metric	2023–2028 Estimates	Source	Comments
CAGR	4–6%	Industry reports	Driven by demographic and regional growth
Market Penetration	25–30% in PAD patients	Market analytics	Coherence with guideline adoption
Revenue	$300–350 million	Margins & sales forecasts	Compression due to patent expiration

Strategic Recommendations

• Invest in Development: Further indication expansion (e.g., stroke, cardiac ischemia).
• Strengthen Regional Presence: Capitalize on growth in Asia-Pacific.
• Mitigate Patent Risks: Develop next-generation formulations or combination therapies.
• Monitor Regulatory Trends: Prepare for potential restrictions on off-label use and safety reporting.

---

Key Takeaways

1. Market drivers such as rising PAD prevalence and favorable clinical evidence underpin cilostazol’s sustained growth prospects.
2. Patent expiries scheduled for the late 2020s pose significant revenue risks, necessitating strategic innovation.
3. Regional differences in approvals and adoption will shape revenue trajectories, with Asia-Pacific offering substantial growth potential.
4. Competitive pressures from existing alternatives and emerging agents require differentiation and pipeline expansion.
5. Regulatory and safety concerns constrain off-label use and influence market access, emphasizing the need for ongoing safety surveillance.

---

FAQs

Q1: When is cilostazol expected to lose patent protection in major markets?
A1: Patent protections in the US and EU are anticipated to expire around 2026–2028, opening pathways for generic competition.

Q2: What are the primary therapeutic indications for cilostazol?
A2: The main approved indication is intermittent claudication due to PAD; off-label uses include stroke prevention and restenosis reduction.

Q3: How does cilostazol compare to other drugs for PAD?
A3: Cilostazol offers superior improvement in walking distance with a relatively favorable safety profile compared to agents like pentoxifylline, though efficacy varies.

Q4: What regulatory challenges might impact cilostazol’s future market?
A4: Variability in approval processes, safety concerns about bleeding risks, and off-label use restrictions could limit market expansion.

Q5: What strategic steps can pharmaceutical companies take post-patent expiry?
A5: Developing new formulations, exploring additional indications, licensing, and expanding regional presence can mitigate revenue decline.

---

References

1. Fowkes FG, et al. "Prevalence of peripheral arterial disease in populations with high cardiovascular risk." Lancet 2013;382(9901):1329-1340.
2. U.S. Food and Drug Administration (FDA). Cilostazol approval documentation, 1999.
3. European Medicines Agency (EMA). Cilostazol summary of product characteristics, 2000.
4. Japanese Ministry of Health, Labour and Welfare. Cilostazol usage data, 1994.
5. Market Research Future. "Global Cilostazol Market Outlook to 2028." 2022.

---